DANIEL BACHNER

Issues related to antitrust and competition policy

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 H.R. 1, One Big Beautiful Bill Act Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Issues related to antitrust and competition policy

Issues related to pharmaceutical tariffs

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Issues related to antitrust and competition policy

S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 2780, Medication Affordability and Patent Integrity Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R. 8816, American Medical Innovation and Investment Act of 2024 Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues

H.R. 830, HELP Copays Act S.1375, HELP Copays Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, Pharmacy Benefit Manager Reform Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program

Issues related to antitrust and competition policy

S.142, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

Issues related to antitrust and competition policy

Issues related to antitrust and mergers & acquisitions

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program and smoothing out-of-pocket costs for patients Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues

H.R. 830, HELP Copays Act S.1375, HELP Copays Act H.R. 5379, Lower Costs, More Transparency Act S. 1339, Pharmacy Benefit Manager Reform Act Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Issues related to the 340B program

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues

H.R. 2673, American Innovation and R&D Competitiveness Act of 2023 Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. S.142, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program Administration plans to combat cancer and address other public health needs

H.R. 2617, Consolidated Appropriations Act, 2023 - provisions related to the Prescription Drug User Fee Act (PDUFA) and corporate taxes

Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues

H.R.5376, Inflation Reduction Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R.2891, Preserve Access to Affordable Generics and Biosimilars Act - all H.R.2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - all H.R.2883, Stop Stalling Access to Affordable Medications - all H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - all Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD tax framework

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act - all H.R. 19, Lower Costs, More Cures Act - all H.R. 5260, Reduced Costs and Continued Cures Act - all S. 2164, Lower Costs, More Cures Act of 2021 - all Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021 & 2022; Notice Requirement for Non-Federal Governmental Plans proposed rule

Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F)

Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) Policy proposals related to the Medicare Party D six protected classes policy

Policy proposals impacting biopharmaceutical supply chain USITC 337 review

H.R. 133, Consolidated Appropriations Act, 2021 - Provisions relating to pharmaceuticals

H.R.5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1416, Affordable Prescriptions for Patients Act of 2019 Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to Medicare Part D and prescription drug pricing H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues

USMCA and related policy issues

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs

Trade Agreements including NAFTA, USMCA and related policy issues

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs

Trade Agreements including NAFTA, USMCA and related policy issues

Trade Agreements including NAFTA, USMCA and related policy issues

Implementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act) Draft legislation relating to economic activity in Puerto Rico

H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues

H.R. 6642, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Transparency policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P) CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads

H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent Settlements H.R. 5340: The Support Technology & Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act of 2018 - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements S. 1390: STRONGER Patents Act of 2017 - Provisions related to reforms of PTAB proceedings and other patent system reforms Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO S. 2554:Patient Right to Know Drug Prices Act - provisions related to notification of agreements to the FTC and DOJ

S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 - Provisions related to increases in the wholesale acquisition costs of prescription drugs Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues Transparency policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Final Rule; Calendar Year (CY) 2018 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule with comment period (CMS-1678-FC) - Revisions to the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2018 Proposed Rule: Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program (CMS-4182-P)

Implementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act) Draft legislation relating to economic activity in Puerto Rico

HImplementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act) Draft legislation relating to economic activity in Puerto Rico

H.R. 2212: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 4710: 340B Protecting Access for the Underserved and Safety-net Entities Act or PAUSE Act - Provisions related to the 340B program H.R. 5247: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 5353; Leonard Lance, Eliminating Opioid Infectious Diseases Act of 2018 H.R. 5598: 340B Optimization Act - Provisions related to transparency in the 340B program H.R. 5687: SOUND Disposal and Packaging Act - To require improved packaging and disposal methods with respect to certain drugs H.R. 6071: SERV Communities Act - Provisions related to transparency in the 340B program H.R. 6142: Reducing Drug Waste Act of 2018 - Action plan and report on vial size waste S. 204: Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness S. 974: CREATES Act of 2017 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 - Provisions related to drug pri S. 2312: HELP Act - Provisions related to 340B progr S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B prog S. 2589: Comprehensive Opioid Recovery Centers Act of 2018 - Provisions related to CDC infection surveillance and other funding Drug cost and pricing policy issues Transparency policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues Limited distribution systems in the pharmaceutical supply chain policy issues FDA modernization policy issues 340B drug discount program policy issues 21st Century Cures Act (Public Law 114-255) - Provisions related to biopharmaceutical discovery, development, delivery, and transparency Senate HELP Committee Innovation Agenda - Provisions related to biopharmaceutical discovery and development of FDA policy Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issue Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Trade Agreements and related policy issue International intellectual property and market access policy issues Pricing and reimbursement policy issues Canada intellectual property and market access policy issues NAFTA policy issues Korea Trade Agreement (KORUS) policy issues

S. 3158: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2019, and for other purposes

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 S. 251: Protecting Medicare from Executive Action Act of 2017 S. 260: Protecting Seniors' Access to Medicare Act of 2017 H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 H.J.Res. 51: Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 16: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act S.J.Res. 17: A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act Part D policy issues including non-interference and rebates policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues H.R. 3921: HEALTHY KIDS Act - Funding for the Childrens Health Insurance Program S. 1827: KIDS Act of 2017 - Funding for the Childrens Health Insurance Program H.R. 3922: Championing Healthy Kids Act - CHIP and CHC reauthorization

H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act)

S. 297: Increasing Competition in Pharmaceuticals Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771: Improving Access to Affordable Prescription Drugs Act H.R. 749: Lower Drug Costs Through Competition Act H.R. 1231: RACE for Children Act H.R. 1245: Affordable and Safe Prescription Drug Importation Act H.R. 1776: Improving Access to Affordable Prescription Drugs Act S. 2312: HELP Act - Provisions related to 340B program S. 2453: Ensuring the Value of the 340B Program Act of 2018 - Provisions to increase transparency in the 340B program H.R. 4710: 340B Preserving Patient Access for the Underserved and Safety-Net Entities Act or PAUSE Act - Provisions related to the 340B program 340B drug discount program policy issues H.R. 749: Lower Drug Costs Through Competition Act S. 469: Affordable and Safe Prescription Drug Importation Act H.Res. 403: Supporting the designation of March 2018 as Endometriosis Awareness Month S.Res.451: A resolution recognizing the significance of endometriosis as an unmet chronic disease for women and designating March 2018 as "Endometriosis Awareness Month"

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues H.R. 3921-Healthy Kids Act S. 1827- Kids Act of 2017

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures Implementation of the Puerto Rico Oversight, Management, and Economic Stability Act House Republican Tax Reform Blueprint and the Joint Statement on Tax Reform

U.S. Trade policy, including IP and pharmaceutical market access issues Japan Pricing and Regulatory Issues U.S. IP policy

S. 124: Preserve Access to Affordable Generics Act S. 1390: STRONGER Patents Act S. 1681: A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceedings at the PTO Bayh-Dole policy issues Venue in patent cases policy issues

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference H.R. 244: Consolidated Appropriations Act, 2017 Budget of the United States Government, Fiscal Year 2018 - A New Foundation for American Greatness Implementation of the Military Construction and Veterans Affairs and Related Agencies H.R. 601: Continuing Appropriations Act, 2018 and Supplemental Appropriations for Disaster Relief Requirements Act, 2017 H.R. 2810: National Defense Authorization Act for Fiscal Year 2018 H.R. 3219: Make America Secure Appropriations Act, 2018 H.R. 3268: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 H.Con.Res. 71: FY18 Budget Resolution S.Con.Res. __: FY 18 Budget Resolution

S. 124: Preserve Access to Affordable Generics Acts S. 1390: STRONGER Patents Act S. 1681: A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services H.R. 4117: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 - Patent settlements: Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceedings at the PTO Bayh-Dole march-in rights policy issues

H.R.1370: Continuing Resolution through January 19, 2018 H.R. 2810: National Defense Authorization Act for Fiscal Year 2018 H.J.Res 123: Continuing Resolution through December 22, 2017 H.R.2998: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018 S. 1519: National Defense Authorization Act for Fiscal Year 2018 S.0000: Department of Defense (Chairmans Mark) - Making appropriations for the Department of Defense for the fiscal year ending September 30, 2018 S.0000: Department of Homeland Security (Chairmans Mark) - Making appropriations for the Department of Homeland Security for the fiscal year ending September 30, 2018, and for other purposes. H.R. 244: Consolidated Appropriations Act of 2017 S. Con. Res. 25: Senate Budget Resolution H. Res 553: House Budget Resolution

U.S. Trade policy, including IP and pharmaceutical market access issues U.S. IP policy

Proposals to reform domestic and international tax structures Implementation of the Puerto Rico Oversight, Management, and Economic Stability Act Tax Reform House Republican Tax Reform Blueprint President Tax Reform Principles Senate Tax Reform Efforts Joint Statement on Tax Reform Tax Reform Unified Framework H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act)

S. 64: Safe and Affordable Drugs from Canada Act of 2017 S. 92: Safe and Affordable Drugs from Canada Act of 2017 S. 297: Increasing Competition in Pharmaceuticals Act S. 469: Affordable and Safe Prescription Drug Importation Act S. 771: Improving Access to Affordable Prescription Drugs Act S. 1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017 H.R. 749: Lower Drug Costs Through Competition Act H.R. 1231: RACE for Children Act S. 456: RACE for Children Act H.R. 1245: Affordable and Safe Prescription Drug Importation Act H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 H.R. 1628: American Health Care Act of 2017 H.R. 1776: Improving Access to Affordable Prescription Drugs Act Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs PL 114-255: 21st Century Cures, implementation H.R. 749: Lower Drug Costs Through Competition Act H.R.2430/S.934: FDA Reauthorization Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act S. 1827: KIDS Act of 2017 H.R. 1703: Medical Product Communications Act of 2017 H.Res. 403: Supporting the designation of March 2018 as Endometriosis Awareness Month

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures Implementation of the Puerto Rico Oversight, Management, and Economic Stability Act House Republican Tax Reform Blueprint and the Joint Statement on Tax Reform

S. 124: Preserve Access to Affordable Generics Act S. 1390: STRONGER Patents Act S. 1681: A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceedings at the PTO Bayh-Dole policy issues Venue in patent cases policy issues

S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation S. 204: Trickett Wendler Right to Try Act of 2017 S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 771: Improving Access to Affordable Prescription Drugs Act H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug approvals and priority review vouchers H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 1231: RACE for Children Act - Provisions related to pediatric studies S. 456: RACE for Children Act - Provisions related to pediatric studies H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation H.R. 1628: American Health Care Act of 2017 H.R. 1776: Improving Access to Affordable Prescription Drugs Act Prescription Drug User Fee Act (PDUFA) reauthorization Biologics User Fee Act (BsUFA) reauthorization 340B drug discount program policy issues Orphan Drug Act policy issues Biologics Price Competition and Innovation Act (BPCIA) implementation issues Patient assistance program policy issues H.R. 2430: FDA Reauthorization Act of 2017 - Provisions related to user fee programs PL 114-255-21st Century Cures, implementation H.R. 749-Lower Drug Costs Through Competition Act Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment H.R.2430/S.934: FDA Reauthorization Act of 2017

S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues S. 1390: STRONGER Patents Act - Provisions related to reforms of Patent Trial and Appeal Board (PTAB) proceedings and other patent system reforms

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference H.R. 244: Consolidated Appropriations Act, 2017 H.R. __: Making appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies programs for the fiscal year ending September 30, 2018, and for other purposes Budget of the United States Government, Fiscal Year 2018 - A New Foundation for American Greatness - Provisions related to non-defense program funding including FDA and NIH and repeal of the Independent Payment Advisory Board (IPAB)

Senate and House Committee Tax Reform Proposals Puerto Rican Economy and Debt Relief Proposals Proposals to reform domestic and international tax structures

S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference

S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 242: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal Part D policy issues including non-interference and rebates policy issues Drug cost and pricing policy issues Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues

S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 2005 & S. 1083, Medicare Drug Savings Act; H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; Medicare payment proposals (MedPAC); Medicare Access and CHIP Reauthorization Act (MACRA);

S. 632, STRONG Patents Act of 2015; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 5573 & S. 3094, Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act; S. 3056, CREATES Act of 2016; Proposals/Initiatives related to international intellectual property protection;

H.R. 2028 & Public Law 114-254, Further Continuing and Security Assistance Appropriations Act, 2017; Other Labor, Health and Human Services Appropriations (no bills introduced); S. 1413, FDA User Fee Protection Act;

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 2005 & S. 1083, Medicare Drug Savings Act; H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015; Medicare payment proposals;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Columbia-America Free Trade Agreement; Saudi Arabia Cancellation of Tender Issue; Japan Biannual Re-Pricing Issue; Plan COLOMBIA;

H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;

H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; H.R. 1537 & S. 1878, Advancing Hope Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; S. 2615, Increasing Competition in Pharmaceuticals Act; Proposals/Initiatives related to international intellectual property protection;

H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029); H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act; Other Labor, Health and Human Services Appropriations (no bills introduced); S. 1413, FDA User Fee Protection Act; FDAs Changes Being Effected Rule;

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act; H.R. 2914, Promoting Integrity in Medicare Act; H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015 H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; Medicare payment proposals (MedPAC); Medicare Access and CHIP Reauthorization Act (MACRA);

H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Columbia-America Free Trade Agreement; Saudi Arabia Cancellation of Tender Issue; Japan Biannual Re-Pricing Issue; Plan COLOMBIA;

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 2005 & S. 1083, Medicare Drug Savings Act; H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015; Medicare payment proposals;

H.R. 880, American Research and Competitiveness Act of 2015; H.R. 1430, Permanent CFC Look-Through Act; H.R. 415 & S. 198, Stop Corporate Inversions Act; S. 1946, Tax Relief Extension Act of 2015; H.R. 1, Tax Reform Act of 2014; Administrations Tax Reform and 2017 Budget Proposals; Senate and House Committee Tax Reform Proposals; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Reps. Boustany and Neal: "Innovation Promotion Act" Discussion Draft Proposals to reform domestic and international tax structures (no bills introduced);

H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; S. 2804, Energy and Water Development and Related Agencies Appropriations Act, 2017 (and related House bill not yet introduced); P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029); Other Labor, Health and Human Services Appropriations (No Bills Introduced); Potential Amendments to Appropriations Bills (not introduced);

H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; H.R. 1537 & S. 1878, Advancing Hope Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; S. 2615, Increasing Competition in Pharmaceuticals Act; Proposals/Initiatives related to international intellectual property protection;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Columbia-America Free Trade Agreement; Saudi Arabia Cancellation of Tender Issue; Japan Biannual Re-Pricing Issue; Plan COLOMBIA;

H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; H.R. 160, Protect Medical Innovation Act of 2015; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; H.R. 5573 & S. 3094, Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act; S. 3056, CREATES Act of 2016; Proposals/Initatives related to international intellectual property protection; H.R. 1806, America COMPETES Reauthorization Act of 2015;

H.R. 1430, Permanent CFC Look-Through Act; H.R. 415 & S. 198, Stop Corporate Inversions Act; S. 2786, Corporate Inverters Earnings Stripping Reform; S. 2895, Pay What You Owe Before You Go Act; H.R. 1809, No Federal Contracts for Corporate Deserters Act; H.R. 248, American Job Protection Act; S. 1946, Tax Relief Extention Act of 2015; Administrations Tax Reform and Budget Proposals; Senate and House Committee Tax Reform Proposals; H.R. 1, Tax Reform Act of 2014 (as introduced in the 113th Congress) H.R. 4900, H.R. 5278 & S. 2328, PROMESA; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Proposals to reform domestic and international tax structures (no bills introduced; Issues related to international tax reform including transitioning to a territorial tax system;

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act; H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015; H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act; * H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; * H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015; S. 1913, Stopping Medication Abuse and Protecting Seniors Act; H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; Medicare payment proposals;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Colombia OECD Accession; Middle East Priorities Briefing; Japanese Consumption Tax;

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 2005 & S. 1083, Medicare Drug Savings Act; H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015; Medicare payment proposals;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Columbia-America Free Trade Agreement; Saudi Arabia Cancellation of Tender Issue; Japan Biannual Re-Pricing Issue; Plan COLOMBIA;

H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;

H.R. 880, American Research and Competitiveness Act of 2015; H.R. 1430, Permanent CFC Look-Through Act; H.R. 415 & S. 198, Stop Corporate Inversions Act; S. 1946, Tax Relief Extension Act of 2015; H.R. 1, Tax Reform Act of 2014; Administrations Tax Reform and 2017 Budget Proposals; Senate and House Committee Tax Reform Proposals; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Reps. Boustany and Neal: "Innovation Promotion Act" Discussion Draft Proposals to reform domestic and international tax structures (no bills introduced);

H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Trade Promotion Authority; Columbia-America Free Trade Agreement; Saudi Arabia Cancellation of Tender Issue; Japan Biannual Re-Pricing Issue; Plan COLOMBIA;